Dr. Lindpaintner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
InterVenn Biosciences
2 Tower Place
South San Francisco, CA 94080- Is this information wrong?
Education & Training
University of Iowa Hospitals and ClinicsFellowship, Cardiovascular Disease, 1989 - 1990- University of Iowa Hospitals and ClinicsFellowship, Cardiovascular Disease, 1984 - 1986
Leopold Franzen University Innsbruck Faculty of MedicineClass of 1979
Certifications & Licensure
MI State Medical License 1981 - 2026
CA State Medical License 2022 - 2026
MA State Medical License 1990 - 2025
IA State Medical License 1984 - 1993
OH State Medical License 1982 - 1984- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.Chirag Dhar, Prasanna Ramachandran, Gege Xu, Chad Pickering, Tomislav Čaval, Maurice Wong, Rachel Rice, Bo Zhou, Apoorva Srinivasan, Paul Aiyetan, Chih-Wei Chu, Kaitly...> ;British Journal of Cancer. 2024 Apr 24
- 4 citationsPlasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy.Chad Pickering, Paul Aiyetan, Gege Xu, Alan Mitchell, Rachel Rice, Yana G Najjar, Joseph Markowitz, Lisa M Ebert, Michael P Brown, Gonzalo Tapia-Rico, Dennie Frederick...> ;Frontiers in Immunology. 2023 Jan 1
- 14 citationsSerum Glycoprotein Markers in Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.Prasanna Ramachandran, Gege Xu, Hector H Huang, Rachel Rice, Bo Zhou, Klaus Lindpaintner, Daniel Serie> ;Journal of Proteome Research. 2022 Apr 1
- Join now to see all
Press Mentions
InterVenn’s Glycoproteomic-Based Biomarker Signature Successfully Predicts Favorable Outcomes in Metastatic Malignant Melanoma Patients Treated with Checkpoint InhibitorsApril 12th, 2021- InterVenn Receives Foundational Patent, CLIA Lab Certification to Develop Clinical Glycoproteomics SolutionsJanuary 13th, 2021
- InterVenn Biosciences Reports Results on Vista™ : A Multi-Indication Liquid Biopsy Research Panel Built on GlycoproteomicsNovember 10th, 2020
- Join now to see all
Grant Support
- Automated Sequencing And Genotyping FacilityNational Center For Research Resources1997
- Genetics Of Cerebrovascular DiseaseNational Heart, Lung, And Blood Institute1995–1997
- Genetics Of Cerebrovascular DiseaseNational Heart, Lung, And Blood Institute1995–1996
- Genetics Of Cerebrovascular DiseaseNational Heart, Lung, And Blood Institute1994
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
